International Stem Cell Corporation (ISCO)
USD 0.12
(20.0%)
USD 0.12
(20.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.39 Million USD | 4.97% |
| 2022 | 5.13 Million USD | 3.82% |
| 2021 | 4.94 Million USD | -6.45% |
| 2020 | 5.28 Million USD | -20.14% |
| 2019 | 6.62 Million USD | -15.08% |
| 2018 | 7.79 Million USD | 13.58% |
| 2017 | 6.86 Million USD | -2.57% |
| 2016 | 7.04 Million USD | -1.3% |
| 2015 | 7.13 Million USD | -0.57% |
| 2014 | 7.17 Million USD | -7.24% |
| 2013 | 7.73 Million USD | 44.12% |
| 2012 | 5.37 Million USD | -6.4% |
| 2011 | 5.73 Million USD | -42.21% |
| 2010 | 9.92 Million USD | 167.97% |
| 2009 | 3.7 Million USD | 65.25% |
| 2008 | 2.24 Million USD | 40.3% |
| 2007 | 1.59 Million USD | -71.19% |
| 2006 | 5.54 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 5.36 Million USD | -0.39% |
| 2024 Q2 | 5.59 Million USD | 4.19% |
| 2023 Q4 | 5.39 Million USD | -4.45% |
| 2023 Q2 | 5.78 Million USD | 8.33% |
| 2023 Q1 | 5.34 Million USD | 4.01% |
| 2023 Q3 | 5.64 Million USD | -2.51% |
| 2023 FY | 5.39 Million USD | 4.97% |
| 2022 FY | 5.13 Million USD | 3.82% |
| 2022 Q2 | 5.41 Million USD | -1.55% |
| 2022 Q3 | 5.04 Million USD | -6.91% |
| 2022 Q1 | 5.5 Million USD | 11.22% |
| 2022 Q4 | 5.13 Million USD | 1.84% |
| 2021 Q2 | 5.61 Million USD | -6.78% |
| 2021 Q3 | 4.93 Million USD | -12.01% |
| 2021 FY | 4.94 Million USD | -6.45% |
| 2021 Q4 | 4.94 Million USD | 0.18% |
| 2021 Q1 | 6.01 Million USD | 13.85% |
| 2020 Q4 | 5.28 Million USD | -9.64% |
| 2020 Q1 | 6.87 Million USD | 3.87% |
| 2020 Q2 | 6.78 Million USD | -1.35% |
| 2020 Q3 | 5.85 Million USD | -13.74% |
| 2020 FY | 5.28 Million USD | -20.14% |
| 2019 Q4 | 6.62 Million USD | -19.85% |
| 2019 Q3 | 8.26 Million USD | -3.29% |
| 2019 Q2 | 8.54 Million USD | -1.41% |
| 2019 FY | 6.62 Million USD | -15.08% |
| 2019 Q1 | 8.66 Million USD | 11.12% |
| 2018 Q4 | 7.79 Million USD | -10.65% |
| 2018 FY | 7.79 Million USD | 13.58% |
| 2018 Q2 | 8.41 Million USD | 12.69% |
| 2018 Q1 | 7.46 Million USD | 8.8% |
| 2018 Q3 | 8.72 Million USD | 3.67% |
| 2017 Q4 | 6.86 Million USD | -13.69% |
| 2017 Q3 | 7.95 Million USD | 4.45% |
| 2017 Q2 | 7.61 Million USD | -3.07% |
| 2017 FY | 6.86 Million USD | -2.57% |
| 2017 Q1 | 7.85 Million USD | 11.5% |
| 2016 Q3 | 7.54 Million USD | -4.08% |
| 2016 Q4 | 7.04 Million USD | -6.56% |
| 2016 FY | 7.04 Million USD | -1.3% |
| 2016 Q2 | 7.86 Million USD | -6.28% |
| 2016 Q1 | 8.38 Million USD | 17.51% |
| 2015 FY | 7.13 Million USD | -0.57% |
| 2015 Q4 | 7.13 Million USD | -1.27% |
| 2015 Q3 | 7.23 Million USD | 5.01% |
| 2015 Q2 | 6.88 Million USD | 2.87% |
| 2015 Q1 | 6.69 Million USD | -6.77% |
| 2014 FY | 7.17 Million USD | -7.24% |
| 2014 Q2 | 6.61 Million USD | -0.56% |
| 2014 Q3 | 6.36 Million USD | -3.79% |
| 2014 Q4 | 7.17 Million USD | 12.81% |
| 2014 Q1 | 6.65 Million USD | -14.05% |
| 2013 Q1 | 6.81 Million USD | 26.91% |
| 2013 Q2 | 6.09 Million USD | -10.52% |
| 2013 Q3 | 6.92 Million USD | 13.59% |
| 2013 Q4 | 7.73 Million USD | 11.72% |
| 2013 FY | 7.73 Million USD | 44.12% |
| 2012 Q3 | 7.11 Million USD | -20.13% |
| 2012 Q4 | 5.37 Million USD | -24.54% |
| 2012 FY | 5.37 Million USD | -6.4% |
| 2012 Q1 | 10.58 Million USD | 84.52% |
| 2012 Q2 | 8.9 Million USD | -15.84% |
| 2011 Q2 | 8.11 Million USD | -14.15% |
| 2011 Q1 | 9.44 Million USD | -4.82% |
| 2011 Q3 | 7.32 Million USD | -9.7% |
| 2011 Q4 | 5.73 Million USD | -21.68% |
| 2011 FY | 5.73 Million USD | -42.21% |
| 2010 Q3 | 9.49 Million USD | -14.57% |
| 2010 Q4 | 9.92 Million USD | 4.56% |
| 2010 FY | 9.92 Million USD | 167.97% |
| 2010 Q1 | 5.6 Million USD | 51.27% |
| 2010 Q2 | 11.11 Million USD | 98.32% |
| 2009 Q3 | 3.04 Million USD | -9.33% |
| 2009 Q2 | 3.35 Million USD | 19.99% |
| 2009 Q1 | 2.79 Million USD | 24.85% |
| 2009 FY | 3.7 Million USD | 65.25% |
| 2009 Q4 | 3.7 Million USD | 21.65% |
| 2008 Q4 | 2.24 Million USD | -23.93% |
| 2008 Q2 | 1.51 Million USD | 13.31% |
| 2008 Q1 | 1.34 Million USD | -16.1% |
| 2008 FY | 2.24 Million USD | 40.3% |
| 2008 Q3 | 2.94 Million USD | 94.02% |
| 2007 Q2 | 3.91 Million USD | -26.99% |
| 2007 Q3 | 2.39 Million USD | -38.66% |
| 2007 Q4 | 1.59 Million USD | -33.39% |
| 2007 FY | 1.59 Million USD | -71.19% |
| 2007 Q1 | 5.35 Million USD | -3.42% |
| 2006 FY | 5.54 Million USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | 5.54 Million USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -233233.333% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -175.254% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 48.929% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -876.237% |
| Rebus Holdings, Inc. | 5000.00 USD | -107700.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 95.861% |
| Qrons Inc. | 420.00 USD | -1283233.333% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -599.415% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 80.711% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1021.615% |
| Skye Bioscience, Inc. | 11.94 Million USD | 54.859% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 86.125% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 25.344% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -6959.224% |
| SQZ Biotechnologies Company | 107.18 Million USD | 94.971% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -276.388% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -7348.352% |
| Mesoblast Limited | 667.9 Million USD | 99.193% |
| Marizyme, Inc. | 22.01 Million USD | 75.517% |
| Genus plc | 1.02 Billion USD | 99.476% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -296.804% |
| Pharming Group N.V. | 462.85 Million USD | 98.835% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -62.692% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -980.076% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -759.649% |
| ContraFect Corporation | 20.67 Million USD | 73.935% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1280.755% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1310.341% |
| IMV Inc. | 31.33 Million USD | 82.798% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -30.004% |
| MultiCell Technologies, Inc. | 126.22 USD | -4270221.661% |
| ONE Bio Corp. | 70.08 Million USD | 92.309% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -473.594% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 95.806% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1148.512% |
| Q BioMed Inc. | 3.51 Million USD | -53.32% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 84.678% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1962.945% |
| Biomind Labs Inc. | 73.81 Thousand USD | -7201.643% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.792% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -272.021% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 82.042% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -96.262% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -684.016% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -107.053% |
| GB Sciences, Inc. | 103.44 Thousand USD | -5110.649% |
| Alpha Cognition Inc. | 2.45 Million USD | -119.805% |
| HST Global, Inc. | 1526.00 USD | -353111.009% |
| CSL Limited | 38.02 Billion USD | 99.986% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -445.565% |
| Halberd Corporation | 10.13 Thousand USD | -53103.04% |
| Enzolytics Inc. | 361.7 Million USD | 98.51% |
| Agentix Corp. | 261.39 Thousand USD | -1962.037% |
| Resverlogix Corp. | 8.11 Million USD | 33.58% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -187.026% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.881% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 88.701% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -742.64% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -23560.068% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 39.771% |
| AVAX Technologies, Inc. | 7.37 Million USD | 26.937% |
| Zenith Capital Corp. | 7410.00 USD | -72639.541% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.841% |
| Ember Therapeutics, Inc. | 184.00 USD | -2929247.826% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1574.922% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1962.258% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -480.843% |
| Kadimastem Ltd | 2.3 Million USD | -133.933% |
| Helix BioMedix, Inc. | 3.02 Million USD | -78.177% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 89.772% |
| BioStem Technologies, Inc. | 14.56 Million USD | 62.982% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -9340.572% |
| LadRx Corporation | 2.3 Million USD | -133.547% |
| Cell Source, Inc. | 195.17 Thousand USD | -2661.681% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1424.248% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1424.248% |
| NovAccess Global Inc. | 62.24 Thousand USD | -8558.913% |
| Affymax, Inc. | 7.44 Million USD | 27.583% |
| Itoco Inc. | 1.4 Million USD | -284.98% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -5534.716% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -4984.906% |
| Mobile Lads Corp. | 52.00 USD | -10365284.615% |
| CytoDyn Inc. | 11.13 Million USD | 51.598% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -3669.969% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -30045.414% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1298.289% |
| SYBLEU INC | 330.46 Thousand USD | -1531.02% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1216.49% |
| Bioxytran, Inc. | 137.63 Thousand USD | -3816.07% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 64.071% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 67.489% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -6722.785% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -523.354% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 28.296% |
| Neutra Corp. | 2851.00 USD | -188956.471% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 83.367% |
| PureTech Health plc | 693.97 Million USD | 99.223% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 33.218% |
| IXICO plc | 15.84 Million USD | 65.981% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 34.919% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.783% |
| CSL Limited | 38.02 Billion USD | 99.986% |
| Cellectis S.A. | 333.99 Million USD | 98.386% |